Company Overview - Shandong Boan Biological Technology Co., Ltd. (06955.HK) is a comprehensive biopharmaceutical company engaged in the development, production, and commercialization of biological drugs, focusing on oncology, autoimmune diseases, ophthalmology, and metabolic diseases [2] - The company has a fully integrated industrial chain covering antibody discovery, cell line development, process development, non-clinical and clinical research, regulatory affairs, and large-scale commercial production [2][3] Financial Performance - As of December 31, 2024, Boan Biological achieved total revenue of 726 million yuan, representing a year-on-year growth of 17.5% [1] - The net profit attributable to shareholders was 73.19 million yuan, showing a significant increase of 161.31% year-on-year [1] - The gross profit margin stood at 74.71%, with a debt-to-asset ratio of 42.34% [1] Market Position - Boan Biological's current price-to-earnings (P/E) ratio is 67.81, ranking 70th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 5.64 [1] - The company has three commercialized products and a pipeline of innovative biological drugs and biosimilars with international intellectual property protection [3] Research and Development - The company focuses on next-generation and controllable T-cell therapy technologies, aiming to develop safer, more effective, and affordable cell therapy products [2][3] - Boan Biological has been recognized as a "National High-tech Enterprise" and has established provincial-level research and engineering centers [3]
博安生物（06955.HK）5月30日收盘上涨18.2%，成交7.77亿港元